NasVax receives Ministry of Health Approval for a Phase 1/2a Clinical Study for Improved Flu Vaccine
NasVax engages in the development of vaccines based on its technology platform for improving the immune response to vaccines and enabling both injection and intranasal administration. This technology utilizes CCS/C, a novel biocompatible adjuvant and delivery system, which has been shown to stimulate not only an increased antibody response but also produce a response in T-cells, hence further improved potency. This potent system opens the way for developing further product applications for preventing or treating both infectious and noninfectious diseases.
The company's adjuvant and delivery technology for improving vaccines is based on joint research by Professors Eli Kedar and Yechezkel Barenholz, co-inventor of a liposomal formulation of doxorubicin for cancer treatment, marketed in the USA by Johnson & Johnson (as DoxilTM) and in Europe by Schering Plough (as Caelyx).
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.